TDC
GLMD icon

Thompson Davis & Co’s Galmed Pharmaceuticals GLMD Stock Holding History

Thompson Davis & Co’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3K Hold
1
– – 0.01% 628
2018
Q2 		$1K Buy
+1
New +$1.45K ﹤0.01% 643

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's GLMD Position: Q3 2018 in Review

Thompson Davis & Co held its Galmed Pharmaceuticals (GLMD) position steady in Q3 2018 at 1 share worth $3K. The position accounts for 0.01% of the portfolio, ranked #628.

Thompson Davis & Co first reported a position in GLMD in Q2 2018 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

  • Thompson Davis & Co held 1 share of Galmed Pharmaceuticals worth $3K as of Q3 2018.
  • Thompson Davis & Co left its Galmed Pharmaceuticals share count unchanged in Q3 2018.
  • Galmed Pharmaceuticals made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #628 holding.
  • Thompson Davis & Co first reported a position in Galmed Pharmaceuticals in Q2 2018 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.